Dr Martens Plc Stock Performance
DOCMF Stock | USD 0.71 0.01 1.43% |
The firm owns a Beta (Systematic Risk) of 0.15, which means not very significant fluctuations relative to the market. As returns on the market increase, Dr Martens' returns are expected to increase less than the market. However, during the bear market, the loss of holding Dr Martens is expected to be smaller as well. At this point, Dr Martens plc has a negative expected return of -0.42%. Please make sure to confirm Dr Martens' treynor ratio, day median price, and the relationship between the information ratio and kurtosis , to decide if Dr Martens plc performance from the past will be repeated in the future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Dr Martens plc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's primary indicators remain nearly stable which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
Begin Period Cash Flow | 117.2 M | |
Total Cashflows From Investing Activities | -25 M |
DOCMF |
Dr Martens Relative Risk vs. Return Landscape
If you would invest 94.00 in Dr Martens plc on December 21, 2024 and sell it today you would lose (23.00) from holding Dr Martens plc or give up 24.47% of portfolio value over 90 days. Dr Martens plc is currently producing negative expected returns and takes up 3.0738% volatility of returns over 90 trading days. Put another way, 27% of traded pink sheets are less volatile than DOCMF, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
Risk |
Dr Martens Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Dr Martens' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Dr Martens plc, and traders can use it to determine the average amount a Dr Martens' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1364
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | DOCMF |
Estimated Market Risk
3.07 actual daily | 27 73% of assets are more volatile |
Expected Return
-0.42 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.14 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Dr Martens is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Dr Martens by adding Dr Martens to a well-diversified portfolio.
Dr Martens Fundamentals Growth
DOCMF Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Dr Martens, and Dr Martens fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on DOCMF Pink Sheet performance.
Return On Equity | 0.64 | |||
Return On Asset | 0.16 | |||
Profit Margin | 0.19 % | |||
Operating Margin | 0.23 % | |||
Current Valuation | 2.75 B | |||
Shares Outstanding | 1 B | |||
Price To Earning | 33.56 X | |||
Price To Book | 5.71 X | |||
Price To Sales | 2.43 X | |||
Revenue | 908.3 M | |||
EBITDA | 265 M | |||
Cash And Equivalents | 228 M | |||
Cash Per Share | 0.23 X | |||
Total Debt | 280.9 M | |||
Debt To Equity | 1.20 % | |||
Book Value Per Share | 0.35 X | |||
Cash Flow From Operations | 184.4 M | |||
Earnings Per Share | 0.21 X | |||
Total Asset | 859.1 M | |||
About Dr Martens Performance
By analyzing Dr Martens' fundamental ratios, stakeholders can gain valuable insights into Dr Martens' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Dr Martens has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Dr Martens has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Martens plc designs, develops, procures, markets, sells, and distributes footwear in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. Martens plc was founded in 1945 and is based in London, the United Kingdom. DR MARTENS operates under Footwear Accessories classification in the United States and is traded on OTC Exchange. It employs 2229 people.Things to note about Dr Martens plc performance evaluation
Checking the ongoing alerts about Dr Martens for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Dr Martens plc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Dr Martens plc generated a negative expected return over the last 90 days | |
Dr Martens plc has some characteristics of a very speculative penny stock | |
Dr Martens plc has high historical volatility and very poor performance | |
About 69.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Dr Martens' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Dr Martens' stock is overvalued or undervalued compared to its peers.
- Examining Dr Martens' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Dr Martens' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Dr Martens' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Dr Martens' pink sheet. These opinions can provide insight into Dr Martens' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for DOCMF Pink Sheet analysis
When running Dr Martens' price analysis, check to measure Dr Martens' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Martens is operating at the current time. Most of Dr Martens' value examination focuses on studying past and present price action to predict the probability of Dr Martens' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Martens' price. Additionally, you may evaluate how the addition of Dr Martens to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |